New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:28 EDTCYCCCyclacel outlines the company's key clinical development objectives
Cyclacel Pharmaceuticals provided an outline of the company's key clinical development objectives for 2014. For Sapacitabine in SEAMLESS, the company plans to continue enrollment and expand study into Europe to at least double enrolling sites, report next interim periodic DSMB review at approximately 300 patients enrolled, report DSMB interim analysis for futility after 212 events, and complete enrollment. For Sapacitabine in MDS, the company plans to announce registration-directed, clinical development plan in 2nd line MDS following treatment failure after hypomethylating agents. For Sapacitabine in solid tumors, the company plans to report updated Phase 1 sapacitabine and seliciclib combination data in patients with solid tumors including those carrying the gBRCA mutation. The company also plans to advance early pipeline.
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
09:08 EDTCYCCOn The Fly: Pre-market Movers
Subscribe for More Information
06:05 EDTCYCCCyclacel Pharmaceuticals 10M share Secondary priced at $1.00
H.C. Wainwright acted as sole book running manager for the offering.
March 3, 2015
17:34 EDTCYCCCyclacel Pharmaceuticals files to sell common stock, no amount given
H.C. Wainwright & Co., LLC will serve as the sole book runner for the offering. While the offering is expected to price before 9:30 am EST on March 4, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use